Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02564562
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : December 4, 2015
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
The study aims to understand, using radiolabelled PF-06463922, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.

Condition or disease Intervention/treatment Phase
Healthy Drug: [14C] PF-06463922 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1 Open-Label, Radiolabeled, Single-Dose Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers
Study Start Date : October 2015
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Arm Intervention/treatment
Experimental: Treatment
Radiolabeled PF-06463922 in healthy volunteers
Drug: [14C] PF-06463922
Single oral dose of 100mg PF-06463922 + [14C] PF-06463922




Primary Outcome Measures :
  1. Mass Balance [ Time Frame: 14 days ]
    Mass balance: Cumulative recovery (%) of total radioactivity in urine and feces.

  2. Metabolic profiling / metabolite identification in plasma, urine, and fecal samples [ Time Frame: 14 days ]
  3. AUCinf [ Time Frame: 14 days ]
    Area Under the Curve From Time Zero to Extrapolated Infinite Time

  4. AUClast [ Time Frame: 14 days ]
    Area under the plasma concentration time profile from time 0 to the time of the last quantifiable concentration (Clast)

  5. kel [ Time Frame: 14 days ]
    Elimination rate constant

  6. Cmax [ Time Frame: 14 days ]
    Maximum observed plasma concentration

  7. Tmax [ Time Frame: 14 days ]
    Time for Cmax

  8. t1/2 [ Time Frame: 14 days ]
    Terminal elimination half life

  9. CL/F [ Time Frame: 14 days ]
    Apparent oral clearance

  10. Ae [ Time Frame: 14 days ]
    Total amount of unchanged drug excreted in the urine from time 0 to discharge day

  11. Ae% [ Time Frame: 14 days ]
    Total amount of unchanged drug excreted in the urine from time 0 to infinity expressed as percent of dose

  12. Clr [ Time Frame: 14 days ]
    Renal Clearance

  13. Crbc [ Time Frame: 14 days ]
    Total radioactivity in RBCs

  14. Vz/F [ Time Frame: 14 days ]
    Apparent volume of distribution following oral administration


Secondary Outcome Measures :
  1. AUC (0-24) [ Time Frame: 14 days ]
    Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 24). It is obtained from AUC (0 - t) plus AUC (t - 24).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lbs)
  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  • Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of Screening.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer).
  • Screening supine blood pressure 140 mm Hg (systolic) or 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure is 140 mm Hg (systolic) or 90 mm Hg (diastolic), the blood pressure should be repeated two more times and the average of the three blood pressure values should be used to determine the subject's eligibility.
  • Screening supine 12-lead ECG demonstrating QTcF (time from ECG Q wave to the end of the T wave corresponding to electrical systole [QT] corrected for the heart rate using the Fredericia's formula) >450 msec or a QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization) >120 msec. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.
  • Subjects with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat, if deemed necessary:

    • Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic pyruvic transminase (SGPT) 3 x upper limit of normal (ULN);
    • Total bilirubin ≥ 1.5x ULN; subjects with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ≤ ULN.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.

Herbal supplements and hormone replacement therapy must be discontinued at least 28 days prior to the first dose of study medication.

  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
  • Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Subjects with a history of irregular bowel movements eg, regular episodes of diarrhea or constipation, irritable bowel syndrome (IBS) or lactose intolerance.
  • Subjects enrolled in a previous radionucleotide study or who have received radiotherapy within 12 months prior to screening or such that total radioactivity would exceed acceptable dosimetry (ie, occupational exposure of 5 rem per year).
  • Subjects whose occupation requires exposure to radiation or monitoring of radiation exposure.
  • Subjects who have used tobacco within 90 days prior to dosing.
  • Male subjects with partners currently pregnant; male subjects able to father children who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of investigational product or longer based upon the compound's half life characteristics.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02564562


Locations
Layout table for location information
United States, Wisconsin
Covance Clinical Research Unit Inc.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT02564562     History of Changes
Other Study ID Numbers: B7461004
First Posted: September 30, 2015    Key Record Dates
Last Update Posted: December 4, 2015
Last Verified: December 2015

Keywords provided by Pfizer:
PF-06463922
[14C]PF-06463922
Human ADME
Radiolabel
Mass Balance
Pharmacokinetics